Skip to main content
Top
Published in: BMC Pediatrics 1/2021

Open Access 01-12-2021 | Dyspnea | Research

Red flags of poor prognosis in pediatric cases of COVID-19: the first 6610 hospitalized children in Iran

Authors: Sedigheh Madani, Sarvenaz Shahin, Moein Yoosefi, Naser Ahmadi, Erfan Ghasemi, Sogol Koolaji, Esmaeil Mohammadi, Sahar Mohammadi Fateh, Amirali Hajebi, Ameneh Kazemi, Erfan Pakatchian, Negar Rezaei, Hamidreza Jamshidi, Bagher Larijani, Farshad Farzadfar

Published in: BMC Pediatrics | Issue 1/2021

Login to get access

Abstract

Introduction

COVID-19 clinical course, effective therapeutic regimen, and poor prognosis risk factors in pediatric cases are still under investigation and no approved vaccinehas been introduced for them.

Methods

This cross-sectional study evaluated different aspect of COVID-19 infection in hospitalized COVID-19 positive children (≺18 years oldwith laboratory confirmed COVID-19 infection, using the national COVID-19 registry for all admitted COVID-19 positive cases from February 19 until November 13,2020, in Iran.

Results

We evaluated 6610 hospitalized children. Fifty-four percent (3268) were male and one third of them were infants younger than 1 year. Mortality rate in total hospitalized children was 5.3% and in children with underlying co-morbidities (14.4%) was significantly higher (OR: 3.6 [2.7-4.7]). Chronic kidney disease (OR: 3.42 [1.75-6.67]), Cardiovascular diseases (OR: 3.2 [2.09-5.11]), chronic pulmonary diseases (OR: 3.21 [1.59-6.47]), and diabetes mellitus (OR: 2.5 [1.38-4.55]), resulted in higher mortality rates in hospitalized COVID-19 children. Fever (41%), cough (36%), and dyspnea (27%) were the most frequent symptoms in hospitalized children and dyspnea was associated with near three times higher mortality rate among children with COVID-19 infection (OR: 2.65 [2.13-3.29]).

Conclusion

Iran has relatively high COVID-19 mortality in hospitalized children. Pediatricians should consider children presenting with dyspnea, infants≺ 1 year and children with underlying co-morbidities, as high-risk groups for hospitalization, ICU admission, and death.
Appendix
Available only for authorised users
Literature
2.
go back to reference Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.CrossRef Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.CrossRef
3.
go back to reference Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, et al. Symptom profiles of a convenience sample of patients with COVID-19—United States, January–April 2020. Morb Mortal Wkly Rep. 2020;69(28):904.CrossRef Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, et al. Symptom profiles of a convenience sample of patients with COVID-19—United States, January–April 2020. Morb Mortal Wkly Rep. 2020;69(28):904.CrossRef
4.
go back to reference Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. Morb Mortal Wkly Rep. 2020;69(15):458. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. Morb Mortal Wkly Rep. 2020;69(15):458.
5.
go back to reference Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8.CrossRef Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8.CrossRef
6.
go back to reference Liu L, Lei X, Xiao X, Yang J, Li J, Ji M, Du W, Tan H, Zhu J, Li B, Jin Z. Epidemiological and clinical characteristics of patients with coronavirus disease-2019 in Shiyan City, China. Front Cell Infect Microbiol. 2020;10:284. Liu L, Lei X, Xiao X, Yang J, Li J, Ji M, Du W, Tan H, Zhu J, Li B, Jin Z. Epidemiological and clinical characteristics of patients with coronavirus disease-2019 in Shiyan City, China. Front Cell Infect Microbiol. 2020;10:284.
7.
go back to reference Burki TK. The Russian vaccine for COVID-19. Lancet Respir Med. 2020;8(11):e85–e6.CrossRef Burki TK. The Russian vaccine for COVID-19. Lancet Respir Med. 2020;8(11):e85–e6.CrossRef
8.
go back to reference Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642–3. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642–3.
9.
go back to reference Rawat M, Chandrasekharan P, Hicar MD, Lakshminrusimha S. COVID-19 in newborns and infants-low risk of severe disease: silver lining or dark cloud? Am J Perinatol. 2020;37(8):845–9.CrossRef Rawat M, Chandrasekharan P, Hicar MD, Lakshminrusimha S. COVID-19 in newborns and infants-low risk of severe disease: silver lining or dark cloud? Am J Perinatol. 2020;37(8):845–9.CrossRef
10.
go back to reference Lingappan K, Karmouty-Quintana H, Davies J, Akkanti B, Harting MT. Understanding the age divide in COVID-19: why are children overwhelmingly spared? Am J Physiol Lung Cell Mol Physiol. 2020;319(1):L39–44.CrossRef Lingappan K, Karmouty-Quintana H, Davies J, Akkanti B, Harting MT. Understanding the age divide in COVID-19: why are children overwhelmingly spared? Am J Physiol Lung Cell Mol Physiol. 2020;319(1):L39–44.CrossRef
11.
go back to reference Shen Q, Guo W, Guo T, Li J, He W, Ni S, et al. Novel coronavirus infection in children outside of Wuhan, China. Pediatr Pulmonol. 2020;55(6):1424–9.CrossRef Shen Q, Guo W, Guo T, Li J, He W, Ni S, et al. Novel coronavirus infection in children outside of Wuhan, China. Pediatr Pulmonol. 2020;55(6):1424–9.CrossRef
12.
go back to reference Yoon S, Li H, Lee KH, Hong SH, Kim D, Im H, et al. Clinical characteristics of asymptomatic and symptomatic pediatric coronavirus disease 2019 (COVID-19): a systematic review. Medicina (Kaunas). 2020;56(9):474.CrossRef Yoon S, Li H, Lee KH, Hong SH, Kim D, Im H, et al. Clinical characteristics of asymptomatic and symptomatic pediatric coronavirus disease 2019 (COVID-19): a systematic review. Medicina (Kaunas). 2020;56(9):474.CrossRef
14.
go back to reference Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir Med. 2021;9(2):e20–e1.CrossRef Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir Med. 2021;9(2):e20–e1.CrossRef
15.
go back to reference Buonsenso D, Di Giuda D, Sigfrid L, Pizzuto DA, Di Sante G, De Rose C, et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child Adolesc Health. 2021;5(9):677–80.CrossRef Buonsenso D, Di Giuda D, Sigfrid L, Pizzuto DA, Di Sante G, De Rose C, et al. Evidence of lung perfusion defects and ongoing inflammation in an adolescent with post-acute sequelae of SARS-CoV-2 infection. Lancet Child Adolesc Health. 2021;5(9):677–80.CrossRef
16.
go back to reference Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for long covid in previously hospitalised children using the ISARIC global follow-up protocol: a prospective cohort study. 2021. Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for long covid in previously hospitalised children using the ISARIC global follow-up protocol: a prospective cohort study. 2021.
18.
go back to reference Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D'Antiga L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771–8. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D'Antiga L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771–8.
19.
go back to reference Singh-Grewal D, Lucas R, McCarthy K, Cheng AC, Wood N, Ostring G, et al. Update on the COVID-19-associated inflammatory syndrome in children and adolescents; paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2. J Paediatr Child Health. 2020;56(8):1173–7.CrossRef Singh-Grewal D, Lucas R, McCarthy K, Cheng AC, Wood N, Ostring G, et al. Update on the COVID-19-associated inflammatory syndrome in children and adolescents; paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2. J Paediatr Child Health. 2020;56(8):1173–7.CrossRef
20.
go back to reference Mamishi S, Movahedi Z, Mohammadi M, Ziaee V, Khodabandeh M, Abdolsalehi MR, et al. Multisystem Inflammatory Syndrome Associated with SARS-CoV-2 Infection in 45 Children: A First Report from Iran; 2020. p. 1–16. Mamishi S, Movahedi Z, Mohammadi M, Ziaee V, Khodabandeh M, Abdolsalehi MR, et al. Multisystem Inflammatory Syndrome Associated with SARS-CoV-2 Infection in 45 Children: A First Report from Iran; 2020. p. 1–16.
21.
go back to reference COVID-19 clinical management, living guidance [Internet]. WHO. 2021. COVID-19 clinical management, living guidance [Internet]. WHO. 2021.
22.
go back to reference Clinical management of severe acute respiratory infection (‎‎ SARI)‎‎ when COVID-19 disease is suspected: interim guidance. World Health Organization; 2020. Clinical management of severe acute respiratory infection (‎‎ SARI)‎‎ when COVID-19 disease is suspected: interim guidance. World Health Organization; 2020.
24.
go back to reference Covid C, COVID C, COVID C, Bialek S, Gierke R, Hughes M, et al. Coronavirus disease 2019 in children—United States, February 12–April 2, 2020. Morb Mortal Wkly Rep. 2020;69(14):422.CrossRef Covid C, COVID C, COVID C, Bialek S, Gierke R, Hughes M, et al. Coronavirus disease 2019 in children—United States, February 12–April 2, 2020. Morb Mortal Wkly Rep. 2020;69(14):422.CrossRef
25.
go back to reference Kim L, Whitaker M, O’Halloran A, Kambhampati A, Chai SJ, Reingold A, et al. Hospitalization rates and characteristics of children aged< 18 years hospitalized with laboratory-confirmed COVID-19—COVID-NET, 14 states, march 1–July 25, 2020. Morb Mortal Wkly Rep. 2020;69(32):1081.CrossRef Kim L, Whitaker M, O’Halloran A, Kambhampati A, Chai SJ, Reingold A, et al. Hospitalization rates and characteristics of children aged< 18 years hospitalized with laboratory-confirmed COVID-19—COVID-NET, 14 states, march 1–July 25, 2020. Morb Mortal Wkly Rep. 2020;69(32):1081.CrossRef
26.
go back to reference Eastin C, Eastin T. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China: Dong Y, Mo X, Hu Y, et al. Pediatrics. 2020. J Emerg Med. 2020;58(4):712–3. Eastin C, Eastin T. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China: Dong Y, Mo X, Hu Y, et al. Pediatrics. 2020. J Emerg Med. 2020;58(4):712–3.
27.
go back to reference Garazzino S, Montagnani C, Donà D, Meini A, Felici E, Vergine G, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Eurosurveillance. 2020;25(18):2000600.CrossRef Garazzino S, Montagnani C, Donà D, Meini A, Felici E, Vergine G, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Eurosurveillance. 2020;25(18):2000600.CrossRef
28.
go back to reference Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663–5.CrossRef Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663–5.CrossRef
29.
go back to reference Parri N, Lenge M, Buonsenso D. Coronavirus infection in pediatric emergency departments research G. children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med. 2020;383(2):187–90.CrossRef Parri N, Lenge M, Buonsenso D. Coronavirus infection in pediatric emergency departments research G. children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med. 2020;383(2):187–90.CrossRef
30.
go back to reference WJ G, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRef WJ G, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRef
32.
go back to reference Xia W, Shao J. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol. 2020;55(5):1169–74.CrossRef Xia W, Shao J. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol. 2020;55(5):1169–74.CrossRef
33.
go back to reference Babaniamansour S, Hematyar M, Babaniamansour P, Babaniamansour A, Aliniagerdroudbari E. The Prevalence of Vitamin D Deficiency Among One to Six Year Old Children of Tehran, Iran, J Kermanshah Univ Med Sci. 2019;23(4):e95185. https://doi.org/10.5812/jkums.95185. Babaniamansour S, Hematyar M, Babaniamansour P, Babaniamansour A, Aliniagerdroudbari E. The Prevalence of Vitamin D Deficiency Among One to Six Year Old Children of Tehran, Iran, J Kermanshah Univ Med Sci. 2019;23(4):e95185. https://​doi.​org/​10.​5812/​jkums.​95185.
34.
go back to reference Rasoulpour FL. Familial aggregation in vitamin D deficiency: Tabriz University of Medical Sciences, Faculty of Medicine; 2020. Rasoulpour FL. Familial aggregation in vitamin D deficiency: Tabriz University of Medical Sciences, Faculty of Medicine; 2020.
35.
go back to reference Pizzini A, Aichner M, Sahanic S, Böhm A, Egger A, Hoermann G, et al. Impact of Vitamin D deficiency on COVID-19—a prospective analysis from the CovILD registry. Nutrients. 2020;12(9):2775.CrossRef Pizzini A, Aichner M, Sahanic S, Böhm A, Egger A, Hoermann G, et al. Impact of Vitamin D deficiency on COVID-19—a prospective analysis from the CovILD registry. Nutrients. 2020;12(9):2775.CrossRef
36.
go back to reference Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25 (OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J. 2020;287(17):3693–702.CrossRef Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, et al. Low plasma 25 (OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J. 2020;287(17):3693–702.CrossRef
37.
go back to reference Boucher BJ. Vitamin D status as a predictor of Covid‐19 risk in Black, Asian and other ethnic minority groups in the UK. Diabetes Metab Res Rev. 2020;36(8):e3375. Boucher BJ. Vitamin D status as a predictor of Covid‐19 risk in Black, Asian and other ethnic minority groups in the UK. Diabetes Metab Res Rev. 2020;36(8):e3375.
38.
go back to reference Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK biobank. Diab Metab Syndr. 2020. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK biobank. Diab Metab Syndr. 2020.
39.
go back to reference Roy AS, Matson M, Herlekar R. Response to 'Vitamin D concentrations and COVID-19 infection in UK Biobank'. Diab Metab Syndr. 2020;14(5):777.CrossRef Roy AS, Matson M, Herlekar R. Response to 'Vitamin D concentrations and COVID-19 infection in UK Biobank'. Diab Metab Syndr. 2020;14(5):777.CrossRef
40.
go back to reference Dror AA, Morozov N, Daoud A, Namir Y, Orly Y, Shachar Y, et al. Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness. medRxiv. 2021. Dror AA, Morozov N, Daoud A, Namir Y, Orly Y, Shachar Y, et al. Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness. medRxiv. 2021.
41.
go back to reference Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Saráchaga M, Salcedo-Lozada P, et al. COVID-19 and multisystem inflammatory syndrome in Latin American children: a multinational study. Pediatr Infect Dis J. 2020;40(1):e1–6.CrossRef Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Saráchaga M, Salcedo-Lozada P, et al. COVID-19 and multisystem inflammatory syndrome in Latin American children: a multinational study. Pediatr Infect Dis J. 2020;40(1):e1–6.CrossRef
42.
go back to reference Preston LE, Chevinsky JR, Kompaniyets L, Lavery AM, Kimball A, Boehmer TK, et al. Characteristics and disease severity of US children and adolescents diagnosed with COVID-19. JAMA Netw Open. 2021;4(4):e215298-e.CrossRef Preston LE, Chevinsky JR, Kompaniyets L, Lavery AM, Kimball A, Boehmer TK, et al. Characteristics and disease severity of US children and adolescents diagnosed with COVID-19. JAMA Netw Open. 2021;4(4):e215298-e.CrossRef
43.
go back to reference Abdoli A. Iran, sanctions, and the COVID-19 crisis. J Med Econ. 2020;23(12):1461–5.CrossRef Abdoli A. Iran, sanctions, and the COVID-19 crisis. J Med Econ. 2020;23(12):1461–5.CrossRef
44.
go back to reference NIH. Potential Antiviral Drugs Under Evaluation for the Treatment of COVID-19. In: NIH, editor. 2020. NIH. Potential Antiviral Drugs Under Evaluation for the Treatment of COVID-19. In: NIH, editor. 2020.
45.
go back to reference Gujski M, Raciborski F, Jankowski M, Nowicka PM, Rakocy K, Pinkas J. Epidemiological analysis of the first 1389 cases of COVID-19 in Poland: a preliminary report. Med Sci Monit. 2020;26:e924702–1.PubMedPubMedCentral Gujski M, Raciborski F, Jankowski M, Nowicka PM, Rakocy K, Pinkas J. Epidemiological analysis of the first 1389 cases of COVID-19 in Poland: a preliminary report. Med Sci Monit. 2020;26:e924702–1.PubMedPubMedCentral
46.
go back to reference Zare-Zardini H, Soltaninejad H, Ferdosian F, Hamidieh AA, Memarpoor-Yazdi M. Coronavirus disease 2019 (COVID-19) in children: prevalence, diagnosis, clinical symptoms, and treatment. Int J Gen Med. 2020;13:477–82.CrossRef Zare-Zardini H, Soltaninejad H, Ferdosian F, Hamidieh AA, Memarpoor-Yazdi M. Coronavirus disease 2019 (COVID-19) in children: prevalence, diagnosis, clinical symptoms, and treatment. Int J Gen Med. 2020;13:477–82.CrossRef
47.
go back to reference Vanhems P, Endtz H, Dananché C, Komurian-Pradel F, Picot VS. Comparison of the clinical features of SARS-CoV-2, other coronavirus and influenza infections in infants less than 1-year-old. Pediatr Infect Dis J. 2020;39(7):e157–e8.CrossRef Vanhems P, Endtz H, Dananché C, Komurian-Pradel F, Picot VS. Comparison of the clinical features of SARS-CoV-2, other coronavirus and influenza infections in infants less than 1-year-old. Pediatr Infect Dis J. 2020;39(7):e157–e8.CrossRef
Metadata
Title
Red flags of poor prognosis in pediatric cases of COVID-19: the first 6610 hospitalized children in Iran
Authors
Sedigheh Madani
Sarvenaz Shahin
Moein Yoosefi
Naser Ahmadi
Erfan Ghasemi
Sogol Koolaji
Esmaeil Mohammadi
Sahar Mohammadi Fateh
Amirali Hajebi
Ameneh Kazemi
Erfan Pakatchian
Negar Rezaei
Hamidreza Jamshidi
Bagher Larijani
Farshad Farzadfar
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2021
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-021-03030-2

Other articles of this Issue 1/2021

BMC Pediatrics 1/2021 Go to the issue